Advances in the development of new biologics in inflammatory bowel disease

 
This item is provided by the institution :

Repository :
Annals of Gastroenterology
see the original item page
in the repository's web site and access all digital files if the item*
share




2016 (EN)
Advances in the development of new biologics in inflammatory bowel disease (EN)

Ungar, Bella
Kopylov, Uri

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infl iximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.Keywords Infl ammatory bowel disease, Crohn's disease, ulcerative colitis, therapy, biologicsAnn Gastroenterol 2016; 29 (3): 243-248 (EN)

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Society of Gastroenterology (EN)

2016-06-27


Hellenic Society of Gastroenterology (EN)

1792-7463
1108-7471
Annals of Gastroenterology; Volume 29, No 3 (2016); 243 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)